Literature DB >> 23673334

Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Nitin Toteja1, Juan A Gallego1, Ema Saito1, Tobias Gerhard2, Almut Winterstein3, Mark Olfson4, Christoph U Correll1.   

Abstract

Antipsychotic polypharmacy (APP), which is common in adults with psychotic disorders, is of unproven efficacy and raises safety concerns. Although youth are increasingly prescribed antipsychotics, little is known about APP in this population. We performed a systematic PubMed search (last update 26 January 2013) of studies reporting the prevalence of APP in antipsychotic-treated youth. Summary statistics and statistical tests were calculated at the study level and not weighted by sample size. Fifteen studies (n = 58 041, range 68-23 183) reported on APP in youth [mean age = 13.4 ± 1.7 yr, 67.1 ± 10.2% male, 77.9 ± 27.4% treated with second-generation antipsychotics (SGAs)]. Data collected in these studies covered 1993-2008. The most common diagnoses were attention-deficit hyperactivity disorder (ADHD; 39.9 ± 23.5%) and conduct disorder/oppositional defiant disorder (CD/ODD; 33.6 ± 24.8). In studies including predominantly children (mean age = <13 yr, N = 5), the most common diagnosis were ADHD (50.6 ± 25.4%) and CD/ODD (39.5 ± 27.5%); while in studies with predominantly adolescents (mean age = ⩾13 yr, N = 7) the most common diagnoses were schizophrenia-spectrum disorders (28.6 ± 23.8%), anxiety disorders (26.9 ± 14.9%) and bipolar-spectrum disorders (26.6 ± 7.0%), followed closely by CD/ODD (25.8 ± 17.7). The prevalence of APP among antipsychotic-treated youth was 9.6 ± 7.2% (5.9 ± 4.5% in child studies, 12.0 ± 7.9% in adolescent studies, p = 0.15). Higher prevalence of APP was correlated with a bipolar disorder or schizophrenia diagnosis (p = 0.019) and APP involving SGA+SGA combinations (p = 0.0027). No correlation was found with APP definition [⩾1 d (N = 10) vs. >30-⩾90 d (N = 5), p = 0.88]. Despite lacking safety and efficacy data, APP in youth is not uncommon, even in samples predominantly consisting of non-psychotic patients. The duration, clinical motivations and effectiveness of this practice require further study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23673334      PMCID: PMC4010557          DOI: 10.1017/S1461145712001320

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  55 in total

1.  Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients.

Authors:  Carol Paton; Paul Lelliott; Maria Harrington; Chike Okocha; Tom Sensky; Richard Duffett
Journal:  J Psychopharmacol       Date:  2003-06       Impact factor: 4.153

2.  Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice--a highly individualized therapy.

Authors:  Kerstin Bingefors; Dag Isacson; Eva Lindström
Journal:  Nord J Psychiatry       Date:  2003       Impact factor: 2.202

Review 3.  Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management.

Authors:  Nancy Scotto Rosato; Christoph U Correll; Elizabeth Pappadopulos; Alanna Chait; Stephen Crystal; Peter S Jensen
Journal:  Pediatrics       Date:  2012-05-28       Impact factor: 7.124

Review 4.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 5.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

Review 6.  A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders.

Authors:  Jovan Simeon; Robert Milin; Selena Walker
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-02       Impact factor: 5.067

7.  10-year trends in the treatment and outcomes of patients with first-episode schizophrenia.

Authors:  Jimmi Nielsen; P le Quach; C Emborg; L Foldager; C U Correll
Journal:  Acta Psychiatr Scand       Date:  2010-11       Impact factor: 6.392

8.  "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings.

Authors:  Elizabeth Pappadopulos; Peter S Jensen; Sarah B Schur; James C MacIntyre; Scott Ketner; Kimberly Van Orden; Jeffrey Sverd; Sadhana Sardana; David Woodlock; Robert Schweitzer; David Rube
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

Review 9.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

10.  Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics.

Authors:  Nick C Patel; Monica Hariparsad; Mary Matias-Akthar; Michael T Sorter; Drew H Barzman; John A Morrison; Kevin E Stanford; Stephen M Strakowski; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-06       Impact factor: 2.576

View more
  19 in total

1.  Are drug-related dental management cautions in Lexicomp Online for Dentistry evidence-based? A systematic review of the literature.

Authors:  Ayesha Qadeer; Temitope T Omolehinwa; Mel Mupparapu; Sunday O Akintoye
Journal:  Quintessence Int       Date:  2019       Impact factor: 1.677

2.  Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.

Authors:  Logan K Wink; Ernest V Pedapati; Paul S Horn; Christopher J McDougle; Craig A Erickson
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-10-14       Impact factor: 2.576

Review 3.  Variation of the prevalence of pediatric polypharmacy: A scoping review.

Authors:  Courtney Baker; James A Feinstein; Xuan Ma; Shari Bolen; Neal V Dawson; Negar Golchin; Alexis Horace; Lawrence C Kleinman; Sharon B Meropol; Elia M Pestana Knight; Almut G Winterstein; Paul M Bakaki
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-06       Impact factor: 2.890

Review 4.  National Child Mental Health Quality Measures: Adherence Rates and Extent of Evidence for Clinical Validity.

Authors:  Bonnie T Zima; Juliet B Edgcomb; Samantha A Shugarman
Journal:  Curr Psychiatry Rep       Date:  2019-01-31       Impact factor: 5.285

5.  Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Authors:  Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn
Journal:  Pharmacotherapy       Date:  2014-07-03       Impact factor: 4.705

6.  Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.

Authors:  Drigissa Ilies; Anne-Sophie Huet; Eric Lacourse; Geneviève Roy; Emmanuel Stip; Leila Ben Amor
Journal:  Can J Psychiatry       Date:  2017-07-04       Impact factor: 4.356

7.  The Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome: Preliminary Evidence from a Case Series.

Authors:  Marco Colizzi; Riccardo Bortoletto; Leonardo Zoccante
Journal:  Children (Basel)       Date:  2021-02-09

Review 8.  Polypharmacy in pediatric patients and opportunities for pharmacists' involvement.

Authors:  Alexis E Horace; Fahamina Ahmed
Journal:  Integr Pharm Res Pract       Date:  2015-08-21

9.  Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment.

Authors:  Gail A Edelsohn; Kemal Eren; Meghna Parthasarathy; Neal D Ryan; Amy Herschell
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

10.  High-level psychotropic polypharmacy: a retrospective comparison of children in foster care to their peers on Medicaid.

Authors:  Deborah Winders Davis; W David Lohr; Yana Feygin; Liza Creel; Kahir Jawad; V Faye Jones; P Gail Williams; Jennifer Le; Marie Trace; Natalie Pasquenza
Journal:  BMC Psychiatry       Date:  2021-06-10       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.